Latest The City of London Migraine Clinic Stories
Individuals who suffer from migraines with aura (temporary visual or sensory disturbances before or during a migraine headache) are at a higher risk of dying from heart disease or stroke.
MOUNTAIN VIEW, Calif., July 13 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc.
A new study provides profound evidence of the cost of chronic migraine in terms of lost productive time at work. CHICAGO, June 25 /PRNewswire-USNewswire/ -- A new analysis from the American Migraine Prevalence and Prevention Study, one of the largest longitudinal studies of headache, indicates that employees suffering from Chronic Migraine (CM) experience increased lost productive time (LPT) in the workplace.
Researchers looking for the first time at how migraine sufferers experience the stigmatizing effects of their disease show that chronic migraine sufferers experience worse stigma than episodic migraine sufferers and more than those with other neurological diseases including stroke, epilepsy and MS.
MOUNTAIN VIEW, Calif., June 10 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX(TM) orally inhaled migraine therapy.
DURHAM, N.C., June 9 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., ("CoLucid"), an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced that its investigational first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), lasmiditan (also known as COL-144), a selective 5-HT1F receptor agonist, was effective when given orally to treat acute migraine attacks, as documented in a Phase IIb study.
CHICAGO, June 9 /PRNewswire/ -- In celebration of National Headache Awareness Week, the National Headache Foundation (NHF), with the support of MAP Pharmaceuticals, Inc.
CHICAGO, June 7 /PRNewswire/ -- If an average day begins as a hectic race to get the kids off to school and get to work on time, imagine starting that day with a migraine.
MOUNTAIN VIEW, Calif., May 11 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today provided an update on its development program for LEVADEX(TM) orally inhaled migraine therapy. LEVADEX has completed Phase 3 efficacy development for the acute treatment of migraine.
MOUNTAIN VIEW, Calif., April 14 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc.
- An imitative word; an onomatopoetic word.